Clover Health Investments, Corp. (CLOV) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Clover Health operates as a Medicare Advantage insurer utilizing its proprietary "Clover Assistant" technology platform to manage chronic diseases and lower costs. The company operates PPO and HMO plans across five states and 200 counties. As of September 30, 2025, the company reported 109,226 members, a significant increase from 81,110 members in the prior year period.
Key Financial Metrics
| Metric (Nine Months Ended Sept 30, 2025) | Value (in thousands) |
|---|---|
| Total Revenues | $1,436,601 |
| Premiums Earned, Net | $1,405,860 |
| Net Medical Claims Incurred | $1,154,907 |
| Net Loss | $(36,229) |
| Adjusted EBITDA (Non-GAAP) | $45,028 |
| Cash and Cash Equivalents | $190,055 |
| Total Investments | $205,900 |
| Unpaid Claims Liability | $140,457 |
Note: The company reported a Net Loss of $24.4 million for the three months ended September 30, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by 38.9% year-over-year (YoY) for the nine months ended September 30, 2025, driven primarily by a 32% increase in average membership.
- Expense Increases: Net medical claims incurred rose 51.3% YoY to $1.15 billion. This increase was attributed to membership growth and higher Part D cost sharing due to the Inflation Reduction Act.
- Widening Losses: Net loss from continuing operations increased by 46.2% YoY to $36.2 million. While revenue grew, operating expenses (including medical claims) grew at a faster rate.
- Benefits Expense Ratio (BER): The gross Benefits Expense Ratio increased to 89.4% for the nine months ended September 30, 2025, compared to 80.6% in the prior year period. The normalized BER was 88.9%.
- Star Ratings: CMS decreased the Star rating for Clover's PPO plans to 3.5 Stars for 2026 (affecting 2027 payments), while the HMO plan rating increased to 4.0 Stars.
Guidance, Outlook, and Risks
- Outlook: Management expects current cash, investments, and projected cash flows to be sufficient to meet obligations for the next 12 months. The company continues to focus on member growth and leveraging its technology to improve medical loss ratios.
- Regulatory Risks: The filing highlights risks related to CMS Risk Adjustment Data Validation (RADV) audits, which CMS announced intentions to significantly increase in May 2025. Changes in Star Ratings directly impact revenue.
- Legal Proceedings: The SEC investigation regarding the 2021 Hindenburg Research article was concluded in September 2024 with no enforcement action recommended. A securities class action was settled in October 2023 for $22 million, funded largely by insurance proceeds.
- Related Party Transactions: CarePoint Health, previously a related party, emerged from bankruptcy in May 2025 and is no longer deemed a related party. Transactions with Thyme Care and Guidehealth continue.
- Investment Accounting Change: The company lost significant influence over Character Biosciences (ownership diluted to ~8.1%) and transitioned accounting from the equity method to fair value measurement, recognizing a $11.3 million fair value adjustment.
Investor Verification Checklist
- Star Rating Impact: Verify the financial impact of the PPO plan Star Rating decrease to 3.5 stars on future 2027 payments.
- Medical Loss Ratio Trend: Monitor the widening gap between premium growth (39%) and medical claim growth (51%) to assess if the business model is achieving cost efficiencies.
- Cash Burn vs. Liquidity: Confirm that the $190 million cash balance and $206 million in investments are sufficient given the $36 million net loss for the nine-month period and ongoing operating cash flow challenges.
- Related Party Exposure: Review the ongoing financial exposure to Thyme Care ($7.2 million payable) and Guidehealth following the exit of CarePoint Health as a related party.
- Regulatory Audits: Assess the potential financial impact of increased CMS RADV audits mentioned in the risk factors.